MORGANTOWN, W.Va. – Radiation oncologists at the WVU Cancer Institute are the first in the state to implement PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), a new treatment for metastatic prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC), which has spread to other parts of the body and has been resistant to other treatments. “Prostate cancer is the second leading Read More…
Sunday, December 22, 2024
Calhoun County’s Daily Source for News & Inspiration
